From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
  • US: C (Risk not ruled out)
Routes of
Legal status
Legal status
Pharmacokinetic data
Bioavailability ~ 50% (32% to 80%)
Protein binding ~ 95%
Metabolism Liver, two P450 isozymes, CYP2D6 and CYP1A2
Biological half-life 12.1 hours
Excretion 70% in urine, 20% in feces
CAS Number 116539-59-4 (free base)
136434-34-9 (hydrochloride)
ATC code N06AX21 (WHO)
PubChem CID 60835
DrugBank APRD00060
ChemSpider 54822
Chemical data
Formula C18H19NOS
Molar mass 297.41456 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Duloxetine (Cymbalta, Yentreve) is a serotonin-norepinephrine reuptake inhibitor manufactured and marketed by Eli Lilly. It is effective for major depressive disorder and it is as effective as venlafaxine in generalized anxiety disorder (GAD). Duloxetine failed the US approval for stress urinary incontinence amidst the concerns about liver toxicity and suicidal events; however, it was approved for this indication in Europe. Duloxetine alleviates pain associated with diabetic neuropathy and fibromyalgia; however, its efficacy relative to the established treatments, such as anticonvulsants and tricyclic antidepressants, has not been studied.

The role of duloxetine in the treatment of various conditions has led to divergent opinions. Some state that owing to a large number of side effects and lack of clear advantage over existing medications, prompted critical reviews concluding that duloxetine "should not be used" for stress urinary incontinence[1] and "currently has no place in the treatment of depression or diabetic neuropathy" as well.[2][3] At the same time, some professional guidelines recommend duloxetine in chronic neuropathic pain, especially diabetic polyneuropathy for which it is first-line, and as an add-on treatment in stress urinary incontinence instead of surgery.[4][5]


Cymbalta 60mg

Duloxetine was created by Lilly researchers. David Robertson, David Wong, a co-discoverer of fluoxetine, and Joseph Krushinski are listed as inventors on the patent application filed in 1986 and granted in 1990.[6] The first publication on the discovery of the racemic form of duloxetine known as LY227942, was made in 1988.[7] The (+)-enantiomer of LY227942, assigned LY248686, was chosen for further studies, because it inhibited serotonin reuptake in rat synaptosomes two times more potently than (–)-enantiomer. This molecule was subsequently named duloxetine.[8]

Initial trials conducted in patients using regimens of 20 mg/day or less did not convincingly demonstrate its efficacy[9] and the dose was increased to as high as 120 mg in subsequent clinical trials.[10]

In 2001 Lilly filed a New Drug Application (NDA) for duloxetine with the US Food and Drug Administration (FDA). However, in 2003 the FDA "recommended this application as not approvable from the manufacturing and control standpoint" because of "significant cGMP (current Good Manufacturing Practice) violations at the finished product manufacturing facility" of Eli Lilly in Indianapolis. Additionally, "potential liver toxicity" and QTc interval prolongation appeared as a concern. The FDA experts concluded that "Duloxetine can cause hepatotoxicity in the form of transaminase elevations. It may also be a factor in causing more severe liver injury, but there are no cases in the NDA database that clearly demonstrate this. Use of duloxetine in the presence of ethanol may potentiate the deleterious effect of ethanol on the liver." The FDA also recommended "routine blood pressure monitoring" at the new highest recommended dose of 120 mg, "where 24% patients had one or more [blood pressure] readings of 140/90 vs. 9% of placebo patients."[11]

After the manufacturing issues were resolved, the liver toxicity warning included in the prescribing information, and the follow-up studies showed that duloxetine does not cause QTc interval prolongation, duloxetine was approved by the FDA for depression and diabetic neuropathy in 2004.[12] In 2007 Health Canada approved duloxetine for the treatment of depression and diabetic peripheral neuropathic pain.[13]

Duloxetine was approved for use of stress urinary incontinence (SUI) in the EU in 2004. In 2005, Lilly withdrew the duloxetine application for stress urinary incontinence (SUI) in the U.S., stating that discussions with the FDA indicated "the agency is not prepared at this time to grant approval ... based on the data package submitted." A year later Lilly abandoned the pursuit of this indication in the U.S. market.[14] [15]

The FDA approved duloxetine for the treatment of GAD in February 2007.[16]


The main uses of duloxetine are in major depressive disorder, general anxiety disorder, stress urinary incontinence, painful peripheral neuropathy and fibromyalgia. In addition, it is being studied for various other indications.

Major depressive disorder

Duloxetine has demonstrated efficacy for the treatment of major depressive disorder. In three out of six well-designed properly controlled pre-marketing trials duloxetine performed better than placebo; the three other trials were inconclusive.[17] Recently, duloxetine was shown to be effective in elderly with recurrent major depressive disorder where it improved cognition, depression, and some pain measures.[18] A meta-analysis of these trials indicated that the effect size of duloxetine as compared with placebo was weak-to-moderate, and similar to other 11 antidepressants studied.[19] The rationale behind the development of duloxetine was that inhibition of the reuptake of both serotonin and norepinephrine would make it work better than selective serotonin reuptake inhibitors (SSRIs), which inhibit only the reuptake of serotonin. However, in a comparative meta-analysis of clinical trials duloxetine appeared to be insignificantly less effective than SSRIs.[20] A head-to-head comparison of duloxetine with an SSRI escitalopram (Lexapro) found duloxetine to be both less tolerable and less effective.[21] Another analysis of the comparative efficacy of modern antidepressants found duloxetine to be significantly, by 30-40%, less efficacious than mirtazapine (Remeron), escitalopram, venlafaxine (Effexor) and sertraline (Zoloft). Duloxetine was similar to fluoxetine (Prozac), fluvoxamine (Luvox) and paroxetine (Paxil). The tolerability of duloxetine was significantly worse than the tolerability of escitalopram and sertraline.[22]

A review in Prescrire International summarizing the existing evidence noted that duloxetine has limited efficacy in depression and no advantages over any other antidepressant. Prescribers observed that, taking into account the risk of hepatic disorders and drug interactions, there is no reason to choose duloxetine when so many other options are available.[2] Similar analysis was presented by Drug and Therapeutics Bulletin, which is a part of the respected BMJ Group.[23]

Stress urinary incontinence

Duloxetine was first reported to improve outcomes in stress urinary incontinence (SUI) in 1998.[24] Systematic reviews with meta-analysis, conducted in 2005 by Cochrane Collaboration[25] and in 2008 by University of Minnesota,[26] concluded that duloxetine failed to cure SUI better than placebo. According to the Cochrane review, some studies showed that episodes of incontinence were reduced by about 50%. This was associated with an improvement in quality of life measurements.[25] According to the University of Minnesota review, duloxetine performed worse than oxybutynin (Ditropan) or tolterodine (Detrol) that cured 18% of the cases, or than pelvic floor muscle training + bladder training, which cured 13% of the cases. In terms of "improvement", that is incomplete cure, duloxetine showed improvement in 11% of patients while pelvic floor muscle training + bladder training showed improvement in 36% of the cases.[26] Significant side effects were common with duloxetine; they were reported as acceptable and about a fifth had to discontinue the medication because of poor tolerance.[25]

In addition, the full report prepared by Minnesota Evidence-based Practice Center for the US government, on which the University of Minnesota review is based, notes that weight reduction would result in improved SUI in 990 adults per 1,000 treated.[27] In the light of the cited data, the report does not mention duloxetine in its policy recommendations. The only recommended interventions are early behavioral changes in weight, physical activity, and pelvic floor muscle training.[27]

The only clinical trial, which directly compared duloxetine with the gold standard of the SUI treatment pelvic floor muscle training (PFMT) was conducted by Eli Lilly and gave mixed results. The incontinence episode frequency in duloxetine group decreased by 57% vs. 35% in the PFTM group. However, the differences in the pad use and quality of life were not statistically significant. To the contrary, 65% patients doing PFTM reported feeling better vs 54% of the patients on duloxetine. 31% of the patients on duloxetine discontinued the trial due to the side effects during the first 12 weeks.[28] In the continuation of this trial more than 91% of the patients on duloxetine experienced side effects.[29]

Summing up the existing evidence, a review in Prescrire International recommends pelvic floor exercises, which are "risk-free and effective in two-thirds to three-quarters of cases", as the first line treatment of SUI. Duloxetine use reduced the frequency of stress incontinence by one episode a day as compared with placebo. "The tangible effect of duloxetine on the quality of life is doubtful, with a maximum gain of five points on a 100-point scale." The review notes that, at best, duloxetine efficacy is "modest and transient, while its adverse effects are numerous and potentially severe."[1]

Diabetic peripheral neuropathy

Duloxetine was approved for the pain associated with diabetic peripheral neuropathy (DPN) based on the positive results of two clinical trials. The average daily pain was measured using 11-point scale, and duloxetine treatment resulted in an additional 1–1.7 points decrease of pain as compared with placebo.[30][31][32] At least 50% pain relieve was achieved in 40–45% of the duloxetine patients vs. 20–22% of placebo patients. The pain almost completely disappeared, decreasing by more than 90%, in 9–14% of duloxetine patients vs. 2–4% of placebo patients. Most of the response was achieved in the first two weeks on the medication. Duloxetine slightly increased the fasting serum glucose; however this effect was deemed to be of "minimal clinical significance".[30]

Duloxetine was not effective for the numbness or tingling, nor for the other complications of diabetes. It reduced the pain without treating the underlying nerve damage.[33] Only tight glycemic control was unequivocally demonstrated to slow the progression of neuropathy.[34][35] Benfotiamine, alpha-lipoic acid and ranirestat have also shown some promise.[35]

The comparative efficacy of duloxetine and established pain-relief medications for DPN is unclear. An independent systematic review in BMJ noted that tricyclic antidepressants (imimpramine and amitriptyline), traditional anticonvulsants and opioids have better efficacy than duloxetine. Duloxetine, tricyclic antidepressants and anticonvulsants have similar tolerability while the opioids caused more side effects.[34] A review in Drug and Therapeutic Bulletin saw no place for duloxetine in the treatment of DPN, based on its high cost and insufficient evidence of the comparative efficacy with tricyclic antidepressants.[3] Another independent review in Prescrire International, considered the moderate pain relief achieved with duloxetine to be clinically insignificant and the results of the clinical trials—unconvincing. The reviewer saw no reason to prescribe duloxetine in practice.[2] The comparative data collected by reviewers in BMC Neurology indicated that amitriptyline, other tricyclic antidepressants and venlafaxine may be more effective. However, the authors noted that the evidence in favor of duloxetine is much more solid.[36]

Generalized anxiety disorder

Duloxetine is just as effective as venlafaxine in the treatment of generalized anxiety disorder with demonstrated improvements in function and quality of life for sufferers. Long-term use of duloxetine prevents relapse of generalized anxiety disorder. According to researchers linked to Eli Lilly, clinical trials have demonstrated that duloxetine is well tolerated both in the short term and the long-term.[37] Other Eli Lilly dependent researchers suggested that duloxetine should be considered a first line treatment for generalized anxiety disorder.[38][39] Although this view was repeated in a recent independent review,[40] the major guidelines such as Maudsley Prescribing Guidelines[41], Mayo Clinic Health Information[42] and Canadian Psychiatric Association Guidelines[43] do not mention duloxetine among the recommended treatment options.


On October 19, 2006, Eli Lilly issued a press release saying they had done trials which found that Cymbalta (duloxetine), at 60 mg once or twice daily, significantly reduced pain in more than half of women treated for fibromyalgia (FM), with and without major depression, according to 12-week data presented at the annual meeting of the American College of Rheumatology. Eli Lilly is in Phase III of its FM trials and is expected to submit a sNDA to the FDA for approval of Cymbalta for FM within the next 12 months. Eli Lilly hopes Cymbalta will be the first FDA approved medication for FM and had been promoting Cymbalta for FM since 2004.[44]

Duloxetine is superior to many other medications for the treatment of fibromyalgia due to its freedom from muscarinic, histaminergic and adrenergic adverse reactions. Its effectiveness in pain relief is believed to be due to its modulation of the nociception system. A meta-analysis of clinical trials has confirmed its pain relief, fatigue reducing properties as well as its effectiveness in improving physical and mental performance.[45]

In the study testing the efficacy of Cymbalta for FM, participants completed several questionnaires to measure the amount of pain and discomfort the disease caused them at the beginning of the study, and then at the end of each of the first two weeks and every second week for the remaining 12 weeks of the study. Researchers also tested the participants for depression.[44]

Women who took Cymbalta had significantly less pain and discomfort than those who took the placebo. For men, who made up only 11% of the study, there was no effect from taking the medication compared with a placebo. Reportedly, depression played no part in whether or not the drug worked to control pain. The change in the level of women's pain was particularly pronounced after a month of taking the drug, then leveled off a bit before dropping again near the end of the study.[44]

However, in one of the primary measures of pain there was no significant difference between the two groups at the end of the 12-week trial. Also, because the trial lasted only 12 weeks, it is impossible to tell how well the drug would control treatment for a longer period of time.[44]

The Food and Drug Administration regulators approved the drug for the treatment of fibromyalgia in June 2008.[46]

Chronic fatigue syndrome

As of January 11, 2007, Eli Lilly is currently enrolling patients for double blind Phase II and Phase III trials of Cymbalta for the use of chronic fatigue syndrome (CFS) in conjunction with the University of Cincinnati.[47] CFS is characterized by severe disabling fatigue of at least six months' duration which cannot be fully explained by an identifiable medical condition.


The following contraindications are listed by the manufacturer:[48]

  • Hypersensitivity - duloxetine is contraindicated in patients with a known hypersensitivity to duloxetine or any of the inactive ingredients.
  • MAOIs - concomitant use in patients taking MAOIs is contraindicated.
  • Uncontrolled narrow-angle glaucoma - in clinical trials, Cymbalta use was associated with an increased risk of mydriasis (dilation of the pupil); therefore, its use should be avoided in patients with uncontrolled narrow-angle glaucoma, in which mydriasis can cause sudden worsening.
  • CNS acting drugs - given the primary central nervous system (CNS) effects of duloxetine, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.
  • Cymbalta and thioridazine should not be co-administered.

Adverse effects

Nausea, somnolence, insomnia, and dizziness are the main side effects, reported by about 10% to 20% of patients.[49]

In a trial for mild major depressive disorder (MDD), the most commonly reported treatment-emergent adverse events among duloxetine-treated patients were nausea (34.7%), dry mouth (22.7%), headache (20.0%) and dizziness (18.7%), and except for headache, these were reported significantly more often than in the placebo group:[50]

Duloxetine and SSRIs have been shown to cause sexual side effects in some patients, both males and females. Although usually reversible, these sexual side effects can sometimes last for months, years, or longer, even after the drug has been completely withdrawn. This disorder is known as post-SSRI sexual dysfunction.[citation needed]

Postmarketing spontaneous reports

Reported adverse events which were temporally correlated to Cymbalta therapy include rash, reported rarely, and the following adverse events, reported very rarely: alanine aminotransferase increased, alkaline phosphatase increased, anaphylactic reaction, angioneurotic edema, aspartate aminotransferase increased, bilirubin increased, glaucoma, hepatitis, hyponatremia, jaundice, orthostatic hypotension (especially at the initiation of treatment), Stevens-Johnson syndrome, syncope (especially at initiation of treatment), and urticaria.[51]

Discontinuation syndrome

During marketing of other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomia, hypomania, tinnitus, and seizures. Although these events are generally self-limiting, some have been reported to be severe. The withdrawal syndrome from duloxetine resembles the SSRI discontinuation syndrome.

When discontinuing treatment with Cymbalta, the manufacturer recommends a gradual reduction in the dose, rather than abrupt cessation, whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. The use a liquid form of the drug may facilitate more gradual tapering."[52]

In MDD placebo-controlled clinical trials of up to nine weeks' duration, systematically evaluating discontinuation symptoms in patients taking duloxetine following abrupt discontinuation found the following symptoms occurring at a rate greater than or equal to 2% and at a significantly higher rate in Cymbalta-treated patients compared to those discontinuing from placebo: dizziness, nausea, headache, paresthesia, vomiting, irritability, and nightmare.[53]


The FDA requires all antidepressants, including duloxetine, to carry a black box warning stating that antidepressants may increase the risk of suicide in persons younger than 25. This warning is based on statistical analyses conducted by two independent groups of the FDA experts that found a 2-fold increase of the suicidal ideation and behavior in children and adolescents, and 1.5-fold increase of suicidality in the 18–24 age group.[54][55][56]

To obtain statistically significant results the FDA had to combine the results of 295 trials of 11 antidepressants for psychiatric indications. As suicidal ideation and behavior in clinical trials are rare, the results for any drug taken separately usually do not reach statistical significance. In line with the general results, duloxetine use in depressed adults insignificantly decreased the odds of suicidality by 12%[55] or 20%[56] depending of the statistical technique used. However, in the subgroup of young adults (18–24 years old) duloxetine increased the odds of suicidality 5-fold, close to statistical significance.[55] There have been no trials of duloxetine in minors.

Several commentators noted that the data FDA used in their analysis of duloxetine-associated suicidality may have been incomplete. According to Arif Khan, the Summary Basis of Approval used by the FDA to approve duloxetine for depression contained only the mention of two completed suicides out of 3490 patients, and the rest of the data was not sufficient to "conduct any meaningful analysis."[57] Jeanne Lenzer wrote in The Independent and Slate Magazine, and this fact was also confirmed by a Lilly spokesman, that another two completed suicides, which occurred in the depression studies ran by the Lilly's Japanese partner Shionogi, have not been reported to the FDA.[58][59] According to Lenzer, four completed suicides also occurred in the trials of duloxetine for stress urinary incontinence (SUI). As these trials failed, the FDA initially insisted that any information about them is a commercial secret and cannot be released.[59] Later, in a short statement the FDA acknowledged that in SUI trials eleven suicide attempts occurred in persons taking duloxetine vs none in the placebo group.[60]

A series of four cases of duloxetine-associated suicidality has been reported. In all four cases depressed patients began having suicidal thoughts after starting on duloxetine or increasing its dose. These thoughts stopped, and the patients returned to normal after duloxetine was discontinued, and they were switched to another antidepressant.[61]

A suicide of 19-year-old Traci Johnson, a healthy volunteer in a duloxetine clinical pharmacology study, was highly publicized. For about a month she had been given high doses of duloxetine, and then she was switched to placebo. Four days after the switch, she hanged herself with her scarf from a shower rod in the bathroom of Lilly Laboratory for Clinical Research.[62][63] The New York Times article mentioned a withdrawal syndrome as a possible reason for this suicide.[63]



Although the exact mechanisms of the antidepressant and central pain inhibitory action of duloxetine in humans are unknown, they are believed to be related to its potentiation of serotonergic and noradrenergic activity in the central nervous system. Preclinical studies demonstrate that duloxetine potently inhibits neuronal serotonin and norepinephrine reuptake,[64] and it has been demonstrated that this inhibition is balanced throughout the dosing range (when compared to venlafaxine in which the inhibition of noradrenaline is low at low doses and raises as the dose escalates).

It is also considered a less potent inhibitor of dopamine reuptake. However, duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors and can therefore be considered to be a selective reuptake inhibitor at the 5-HT and NA transporters. Duloxetine undergoes extensive metabolism, but the major circulating metabolites do not contribute significantly to the pharmacologic activity.


Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state is usually achieved after 3 days.

Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP1A2.

When orally administered it is well absorbed. There is an average 2-hour lag until absorption begins with maximum plasma concentrations occurring about 6 hours post dose. Food does not affect the Cmax of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours. Duloxetine is highly bound (>90%) to proteins in human plasma, binding primarily to albumin and α1-acid glycoprotein.

Metabolism and Elimination — Only trace amounts (<1%) of unchanged duloxetine are present in the urine and most of the dose (aprox 70%) appears in the urine as metabolites of duloxetine with about 20% excreted in the feces.


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


es:Duloxetina fr:Duloxétine it:Duloxetina he:דולוקסטין ja:デュロキセチン pl:Duloksetyna pt:Duloxetina ru:Дулоксетин

  1. 1.0 1.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. 2.0 2.1 2.2 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. 3.0 3.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. National Institute for Health and Clinical Excellence. Clinical guideline 40: Urinary incontinence. London, 2006.
  5. National Institute for Health and Clinical Excellence. Clinical guideline 96: Neuropathic pain - pharmacological management. London, 2010.
  6. Robertson DW, Wong DT, Krushinski JH (1990-09-11). "United States Patent 4,956,388: 3-Aryloxy-3-substituted propanamines". USPTO. Retrieved 2008-05-17. 
  7. Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR (1988). "LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug". Life Sci. 43 (24): 2049–57. doi:10.1016/0024-3205(88)90579-6. PMID 2850421. 
  8. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  9. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  10. For example, see: Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  11. "Approval package for: application number NDA 721-427. Administrative/Correspondence #2" (PDF). The FDA Center for Drug Evaluation and Research. 2003. Retrieved 2008-05-18. 
  12. FDA news
  13. Health Canada Notice of Compliance Database - duloxetine. November 1, 2007, retrieved November 24, 2007.
  14. Steyer R (2006-02-15). "Lilly Won't Pursue Yentreve for U.S." TheStreet.com. Retrieved 2008-05-18. 
  15. Lenzer, J. (2005). "FDA warns that antidepressants may increase suicidality in adults". BMJ. 331 (7508): 70. doi:10.1136/bmj.331.7508.70-b. PMC 558648Freely accessible. PMID 16002878.  edit
  16. [1] News-Medical.Net February 26, 2007
  17. Andreason PJ. "Clinical review for NDA 21-427 Cymbalta (duloxetine)" (PDF). CDER approval package for application number 21-427. Medical review # 3. FDA. p. 12. Retrieved 2008-05-22. 
  18. http://ajp.psychiatryonline.org/cgi/content/abstract/164/6/900?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=duloxetine&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
  19. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  20. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  21. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  22. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  23. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  24. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  25. 25.0 25.1 25.2 Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA (2005). "Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults". Cochrane Database Syst Rev (3): CD004742. doi:10.1002/14651858.CD004742.pub2. PMID 16034945. 
  26. 26.0 26.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  27. 27.0 27.1 http://www.ahrq.gov/downloads/pub/evidence/pdf/fuiad/fuiad.pdf
  28. "Trial 2615a Efficacy and Safety of Duloxetine compared with Placebo, Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects with Moderate to Severe Stress Urinary Incontinence" (PDF). www.clinicalstudyresults.org. Retrieved 02-03-09.  Check date values in: |access-date= (help)
  29. "Trial 2615b. Efficacy and Safety of Duloxetine compared with Placebo, Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects with Moderate to Severe Stress Urinary Incontinence" (PDF). www.clinicalstudyresults.org. Retrieved 02-03-09.  Check date values in: |access-date= (help)
  30. 30.0 30.1 Josefberg H (2004-09-03). "Application number 21-733. Medical review(s)" (PDF). FDA. Retrieved 2009-04-14. 
  31. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  32. Raskin J, Pritchett YL, Wang F; et al. (2005). "A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain". Pain Med. 6 (5): 346–56. doi:10.1111/j.1526-4637.2005.00061.x. PMID 16266355. 
  33. Essential Science Indicators
  34. 34.0 34.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  35. 35.0 35.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  36. Sultan A, Gaskell H, Derry S, Moore RA (2008). "Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials". BMC Neurol. 8: 29. doi:10.1186/1471-2377-8-29. PMC 2529342Freely accessible. PMID 18673529. 
  37. One of the authors, HJ Möller "has participated in speakers bureau for Eli Lilly, has been a member of advisory board for Eli Lilly and has received grant/research support from Eli Lilly [2]Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  38. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  39. Disclosure information for Susan Kornstein, see: Wohlreich MM, Wiltse CG, Desaiah D; et al. (2007). "Duloxetine in Practice-Based Clinical Settings: Assessing Effects on the Emotional and Physical Symptoms of Depression in an Open-Label, Multicenter Study". Prim Care Companion J Clin Psychiatry. 9 (4): 271–279. PMC 2018841Freely accessible. PMID 17934551. 
  40. Carter NJ, McCormack PL (2009). "Duloxetine: a review of its use in the treatment of generalized anxiety disorder". CNS Drugs. 23 (6): 523–41. doi:10.2165/00023210-200923060-00006. PMID 19480470. 
  41. Kerwin, Robert; Taylor, David H.; Carol Paton (2007). Maudsley Prescribing Guidelines. Informa Healthcare. p. 254. ISBN 0-415-42416-X. 
  42. "Generalized anxiety disorder: Treatments and drugs - MayoClinic.com". Retrieved 2009-11-28. 
  43. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  44. 44.0 44.1 44.2 44.3 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  45. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  46. "FDA Approves Cymbalta for the Management of Fibromyalgia". Eli Lilly Co. 2008-06-16. Retrieved 2008-06-17. 
  47. [3] Clinicaltrials.gov
  48. http://www.cymbalta.com/learnaboutcymbalta/importantsafetyinformation.jsp?type=print>
  49. Cymbalta package insert. Indianapolis, IN: Eli Lilly Pharmaceuticals; 2004, September.
  50. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  51. [4] Cymbalta Side Effects, and Drug Interactions - RxList Monographs
  52. Cymbalta patient information sheet. Indianapolis, IN: Eli Lilly Pharmaceuticals; July 2006
  53. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  54. Levenson M, Holland C. "Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)". Retrieved 2007-05-13. 
  55. 55.0 55.1 55.2 Stone MB, Jones ML (2006-11-17). "CLINICAL REVIEW: RELATIONSHIP BETWEEN ANTIDEPRESSANT DRUGS AND SUICIDALITY IN ADULTS" (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA. pp. 11–74. Retrieved 2007-09-22. 
  56. 56.0 56.1 Levenson M, Holland C (2006-11-17). "Statistical Evaluation of Suicidality in Adults Treated with Antidepressants" (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA. pp. 75–140. Retrieved 2007-09-22. 
  57. Khan A, Schwartz K (2007). "Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports". Ann Clin Psychiatry. 19 (1): 31–6. doi:10.1080/10401230601163550. PMID 17453659. 
  58. Jeanne Lenzer (2005-09-27). "What the FDA isn't telling". Slate Magazine. Retrieved 2008-01-20. 
  59. 59.0 59.1 Jeanne Lenzer and Nicholas Pyke (2005-06-05). "Was Traci Johnson driven to suicide by anti-depressants? That's a trade secret, say US officials". Independent Online Edition. Retrieved 2008-01-20. 
  60. "Historical Information on Duloxetine hydrochloride (marketed as Cymbalta)". FDA. 2005-06. Retrieved 2008-01-20.  Check date values in: |date= (help)
  61. Parikh AR; Thatcher BT; Tamano EA; Liskow BI (2008). "Suicidal Ideation Associated With Duloxetine Use: A Case Series". J Clin Psychopharmacolgy. 28 (1): 102. 
  62. Walter F. Naedele (2004-02-12). "Drug test altered in wake of suicide". Philadelphia Inquirer. Retrieved 2008-01-20. 
  63. 63.0 63.1 Gardiner Harris (2004-02-12). "Student, 19, in Trial of New Antidepressant Commits Suicide". New York Times. Retrieved 2008-01-20. 
  64. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. "Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors". Neuropsychopharmacology. 2001 Dec;25(6):871-80